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1Evidera Inc., Bethesda, MD, USA; 2AbbVie Inc., North Chicago, IL, USAA B S T R A C TObjective: The objective was to evaluate the psychometric properties
of the Rheumatoid Arthritis-Work Instability Scale (RA-WIS) in a
clinical trial setting. Methods: Secondary analyses were conducted
using data from a 56-week, randomized controlled trial of patients
with early rheumatoid arthritis (RA). Patient-reported outcome meas-
ures included the RA-WIS, the Health Assessment Questionnaire
(HAQ), the Rheumatoid Arthritis Quality of Life Questionnaire, and
the Global Assessment of Disease Activity and Pain, data for which
were collected at baseline and at weeks 12, 16, 24, and 56. Data were
analyzed for reliability, validity, and responsiveness. Results: Among
148 patients whose data were analyzed, more than half were women
(56.1%) with a mean age of 46.8 years. On average, patients experi-
enced RA symptoms for 8.7 months; the mean 28-Joint Disease
Activity Score (DAS28) was 5.9, and the mean HAQ – Disability Index
was 1.3. The RA-WIS demonstrated excellent internal consistency and
test-retest reliability (α ¼ 0.89 and intraclass correlation coefﬁcient ¼
0.91, respectively). At baseline and week 24, moderate to strongee front matter Copyright & 2015, International S
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ndence to: Dennis Revicki, Evidera Inc., 7101 Wisccorrelations were seen between RA-WIS total scores and the HAQ,
the Global Assessment of Disease Activity, and the Pain Rheumatoid
Arthritis Quality of Life Questionnaire, ranging from 0.47 to 0.81 (all Po
0.0001). Mean RA-WIS total scores and work disability risk levels
discriminated between clinical severity scores on the DAS28, the
HAQ – Disability Index, and the Physician Global Assessment of Disease
Activity (all P o 0.05). Mean baseline to week 24 RA-WIS total change
scores were signiﬁcantly different among American College of Rheu-
matology responder groups (P r 0.0001) and between DAS28 remission
status groups (Po 0.001). Conclusions: These ﬁndings provide evidence
supporting the reliability, validity, and responsiveness of the RA-WIS for
evaluating work disability in patients with RA in a clinical trial setting.
Keywords: reliability and validity, rheumatoid arthritis, work disability,
work instability.
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Approximately 20% of the patients with early rheumatoid arthri-
tis (RA) become permanently work disabled during the ﬁrst 2 to 3
years of disease [1–5], and the frequency of work disability
increases over time with approximately one-third of all patients
becoming work disabled within 10 years of diagnosis [5,6]. In
early RA, aggressive treatment has been shown to reduce func-
tional disability [7–12] and positively affect employment out-
comes [7,13–18].
Work instability (WI), a less frequently evaluated construct,
relates to an individual’s ability to fulﬁll normal work tasks and
refers to individuals having to make adjustments or job changes due
to amismatch between their functional capabilities and job demands
[19]. WI is viewed as a transient, potentially reversible state [19] in
which individuals are vulnerable to job loss and interventions are of
greatest preventive importance in relation to work.The Rheumatoid Arthritis-Work Instability Scale (RA-WIS)
was developed to assess the level of risk for work disability in
patients with RA, providing clinicians with an effective screening
tool to facilitate early, appropriate referral for job retention
measures [19]. Initial work to develop the RA-WIS was conducted
in patients with early RA and included 1) qualitative interviews to
identify themes relevant to patients in relation to maintaining
work; 2) assessment of criterion validity against the criterion
standard (i.e., full vocational assessments); and 3) Rasch analysis
to assess discriminative properties and unidimensionality [19].
The initial research on the RA-WIS provides evidence of
content and criterion validity and good test-retest reliability
[19–21]. Additional studies have supported the reliability, validity,
and responsiveness of the RA-WIS in people with RA [22–25].
Beaton et al. [22] demonstrated the relationship between the
RA-WIS and other work productivity measures cross-sectionally
and over 12 months.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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with qualitative assessment to support content validity and
quantitative assessment to support reliability, validity, and abil-
ity to detect change. Psychometric evaluation is also a cumulative
process by which supportive evidence from multiple studies
conducted in different patient populations adds conﬁdence that
the measure is psychometrically sound and appropriate for use in
multiple settings. The objective of this study was to evaluate the
psychometric properties of the RA-WIS in a clinical trial setting in
patients with early RA to provide further evidence for the
suitability of this measure in general and speciﬁcally for use as
an end point in clinical trials. This is the ﬁrst psychometric
evaluation of the RA-WIS based on longitudinal data from a
clinical trial population comparing treatment in patients with
early RA.Methods
Research Design and Study Population
This study was a secondary analysis of data from the PRevention
Of Work Disability (PROWD) study—a 56-week, randomized,
double-blind, comparator-controlled, phase IIIb trial of metho-
trexate (MTX)-naive patients with early RA. A total of 148 patients
were randomized to receive adalimumab 40 mg subcutaneous
injections every other week plus weekly oral MTX (7.5–25 mg)
(n ¼ 75) or placebo every other week plus weekly oral MTX (n ¼
73). Patients were eligible to participate in the study if they had
RA based on the 1987 revised American College of Rheumatology
(ACR) classiﬁcation criteria [26] with less than 2 years of symptom
duration, were 18 years or older, were in paid employment, had
self-reported RA-related work impairment, and were MTX/bio-
logic naive. Patients with active infections, including tuberculo-
sis, previous malignancy, and uncontrolled concomitant illness,
were excluded. Patients were given the option to discontinue
from the trial at week 16 for reasons of loss of employment,
imminent employment loss, lack of efﬁcacy or adverse effects
(N ¼ 40; adalimumab, n ¼ 15; placebo, n ¼ 25). Among those who
discontinued the trial at week 16, 75% did so because of loss of
employment [7]. A detailed description of the study design has
been previously reported [7].
Patient-Reported Outcome Measures
Demographic and medical history data were collected at baseline
along with the following patient-reported outcome (PRO) meas-
ures: RA-WIS, Health Assessment Questionnaire – Disability
Index (HAQ-DI), Patient Global Assessment of Disease Activity,
Patient Assessment of Pain (visual analogue scale [VAS]), RA
Quality of Life Questionnaire (RAQoL), Work Disability Assess-
ment, and Weekly Work Diary. Data for the RA-WIS, HAQ-DI,
RAQoL, and VAS measures were also collected 4 weeks before
baseline and at weeks 12, 16, 24, and 56.
Rheumatoid arthritis-work instability scale
The RA-WIS is a 23-item questionnaire with a “yes/no” response
scale covering a broad range of speciﬁc work-related issues with a
recall period of “at the moment.” Item scores are summed and
range from 0 to 23, with higher scores reﬂecting greater WI and
higher risk for work disability. Scores greater than 17 indicate
high risk for work disability, scores between 10 and 17 indicate
moderate WI, and scores less than 10 indicate low WI [19].
Health assessment questionnaire
The HAQ-DI consists of 20 questions on activities of daily living
with a recall period of “the past week” [27]. Scores are continuousand range from 0 (no difﬁculties performing tasks) to 3 (total
inability to perform tasks) [27]. Research suggests that a mean
score change of –0.22 is considered clinically meaningful in
patients with RA [28,29].Disease assessment VASs
Three VAS scales were used to assess disease: 1) Physician Global
Assessment of Disease Activity, 2) Patient Global Assessment of
Disease Activity, and 3) Patient Assessment of Pain. For assess-
ments of disease activity, either physicians or patients rate
patients’ current RA disease activity from 0 (no symptoms) to
100 (very active). For assessment of pain, patients rate their pain
within the past week from a score of 0 (no pain) to 100
(severe pain).RA quality of life questionnaire
The RAQoL consists of 30 items designed to assess quality of life
(QOL) in people with RA [30]. Each item is in the form of a simple
statement (e.g., “I have difﬁculty dressing”) with a “yes/no”
response scale. Each item is given a score of “1” (item afﬁrmed)
or “0” (item not afﬁrmed). Item scores are summed to give a total
score that ranges from 0 (good QOL) to 30 (poor QOL) [30].Work disability assessment
The Work Disability Assessment evaluates the impact of RA on
work, including time in current job (in years), ability to work, total
hours normally worked per week, sick leave since onset of RA,
modiﬁcation of job since onset of RA, adaptation of working
environment since onset of RA, seeking assistance regarding
employment since onset of RA, and seeing a work disability
advisor because of RA. A “yes/no” response scale is used for most
questions.Weekly work diary
The Weekly Work Diary is a detailed record of patients’ work
practices and speciﬁcally evaluates the number of hours worked
each day of the week and days of the week worked, whether the
hours worked were the normal hours of working for each day, the
number of working hours lost for each day of the week, and
whether the hours of work lost were due to RA. Impact on work
performance was assessed using a VAS anchored from 0 to 100.Demographic Characteristics
Data on demographic and social/medical history variables such
as date of birth, sex, race, and ethnicity were collected at
baseline.Clinical Outcome Measures
Disease activity and joint counts were assessed at screening
(week –4), baseline (week 0), and weeks 12, 16, 24, and 56.Swollen joint counts and tender joint counts
Twenty-eight joints were examined for swelling and joint pain/
tenderness. Swelling and joint pain/tenderness were classiﬁed as
present (“1”), absent (“0”), or replaced (“9”), in the case of
endoprosthesis.Morning stiffness of joints
The average daily duration of morning stiffness (for the preceding
week) was noted in minutes, up to a maximum of 720 minutes.
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The Disease Activity Score (DAS) is a combined index that has
been developed to measure the disease activity in patients with
RA [31]. The 28-Joint DAS (DAS28) is measured using the number
of swollen joint counts (SJCs) and tender joint counts (TJCs),
erythrocyte sedimentation rate, and a patient’s general health or
global disease activity VAS. The DAS calculation provides a
number between 0 and 10, indicating how active RA is at that
moment. DAS28 scores are interpreted as follows: remission
(DAS28r 2.6), low disease activity (2.6o DAS28r 3.2), moderate
disease activity (3.2 o DAS28 r 5.1), and high disease activity
(DAS28 4 5.1) [32].
The ACR criteria for improvement are based on improvement
in both SJCs and TJCs and in three of the following measures:
Patient Global Assessment of Disease Activity, Physician Global
Assessment of Disease Activity, erythrocyte sedimentation rate,
pain scale, and physical function (e.g., HAQ-DI) [33]. Improvement
is denoted as ACR 20, ACR 50, or ACR 70, reﬂecting an improve-
ment of 20%, 50%, or 70% in the outlined parameters.Statistical Analysis
The psychometric analyses of the RA-WIS were prespeciﬁed in an
a priori statistical analysis plan. The psychometric analyses
combined data from both treatment groups and were performed
blinded to treatment group status. All statistical tests used a
signiﬁcance level of 0.05 unless otherwise noted.Descriptive statistics
Means and frequencies were used to describe the following
variables at baseline: sociodemographic characteristics, clinical
factors, and PRO assessments.Reliability
Internal consistency of the RA-WIS items was evaluated using
the Kuder-Richardson 20 formula for internal consistency reli-
ability for dichotomous scales. The reproducibility of the RA-WIS
total score was assessed using intraclass correlation coefﬁcients
(ICCs), paired t tests, and Pearson product-moment correlations
between visit 1 (week –4) and visit 2 (week 0). Only patients
considered stable were included in this analysis, deﬁned as
having less than a 0.22 change in HAQ-DI scores between visit 1
and visit 2. ICC values of more than 0.70 are generally considered
acceptable [34].Construct validity
Spearman correlations were calculated to evaluate relationships
between the RA-WIS total score and clinical assessments and
RAQoL, HAQ-DI, Patient Global Assessment of Disease Activity,
and Patient Assessment of Pain at baseline and week 24. The
construct of WI for the RA-WIS is based on items that assess
speciﬁc job effects and emotional and physical effects. Because
the RA-WIS measures multiple components of work impact, we
anticipated that the construct of WI would be associated with
individual measures that assess each of these constructs. We
hypothesized that moderate to large correlations will be observed
between the RA-WIS total score and the measures of disease
severity, pain, and quality of life. Construct validity was sup-
ported when the RA-WIS total score was correlated with a clinical
or PRO measure with coefﬁcient r 4 0.40, reﬂecting a moderately
strong relationship [35]. Correlation coefﬁcients greater than 0.5
are considered large (strong) and those less than 0.2 are consid-
ered small (weak).Known-groups validity
The ability of RA-WIS total scores to discriminate between groups
of patients according to clinical severity was assessed using
analysis of variance with Scheffe’s post hoc comparisons to
evaluate mean differences between groups at baseline and week
24. Clinical severity categories for the HAQ-DI, DAS28, Physician
Global Assessment of Disease Activity, and work hours lost per
week because of RA were based on quartile distributions from
descriptive analysis.
Known-groups validity for the RA-WIS by work disability risk
categories was assessed using chi-square statistics. Clinical
severity categories were the same as those previously described
for the analysis of RA-WIS total scores. RA-WIS risk categories
were deﬁned as high, medium, or low.Responsiveness
An anchor-based analytic approach was used to assess the
relationship between changes in clinical and work status and
changes in RA-WIS total scores [36]. Mean changes in RA-WIS
scores were assessed for two time frames (from baseline to weeks
24 and 56) among the following disease activity groups: Clinical remission (DAS28 o 2.6 at weeks 24 and 56) versus
nonresponder (DAS28 Z 2.6 at weeks 24 and 56); Clinical responders (DAS28 response of good [score r3.2], or
moderate [score 43.2 and r5.1], based on the European
League Against Rheumatism (EULAR) criteria at weeks 24
and 56) versus DAS28 nonresponders; and Clinical responders (ACR responses of 20%, 50%, and 70% at
weeks 24 and 56) versus nonresponders (ACR response o20%
at weeks 24 and 56).
The RA-WIS total baseline to weeks 24 and 56 change scores
were adjusted for age, sex, and baseline RA-WIS total scores and
were compared using analysis of covariance models with clinical
status as the independent factor.Results
Descriptive Statistics
Sociodemographic and clinical characteristics
A total of 148 patients with a mean age of 46.8 years were
included in the analysis sample. Women (n ¼ 83 [56.1%])
comprised slightly more than half of the sample, and most (n ¼
141 [95.3%]) were white. A detailed description of patient charac-
teristics has previously been published [7].
On average, patients in this trial experienced RA symptoms
for 8.7 months with DAS28 of 5.9, suggesting early and severe
disease. Patients experienced some difﬁculty performing their
daily tasks (mean HAQ-DI scores of 1.3), with greater than four-
ﬁfths of the patients having medium or high risk of work
disability (Table 1). Patients reported losing approximately 5
hours of work per week on average because of RA. Sixty percent
reported using sick leave since the onset of RA, and 23.7%
required modiﬁcation to their job after the onset of RA. RA
impact on work performance was 50.9  30.5. On the basis of
RA-WIS distribution frequency at baseline (N ¼ 145), most of the
patients reported experiencing work-related difﬁculties related to
having stamina (86.9%), experiencing stiffness (86.2%), experienc-
ing pressure in the hands (86.9%), or having good and bad days at
work (91.7%).
Table 1 – Baseline patient-reported outcomes.
Outcome Value
(N ¼ 148)
RA-WIS,* mean  SD 15.3  5.5
Work disability risk based on RA-WIS,† n (%)
High 58 (39.2)
Medium 66 (44.6)
Low 23 (15.5)
Missing 1 (0.7)
RAQoL,‡ mean  SD 16.7  7.4
HAQ-DI,§ mean  SD 1.3  0.6
Patient Global Assessment of Disease Activity,ǁ
mean  SD
61.5  25.6
Patient Assessment of Pain,¶ mean  SD 62.4  25.0
Time in current job (y), mean  SD 11.6  12.1
Total hours normally worked per week, mean  SD 35.7  12.3
Sick leave since onset of RA, n (%) 89 (60.1)
Modiﬁcation of job since onset of RA, n (%) 35 (23.7)
Adaptation of working environment since onset of
RA, n (%)
18 (12.2)
Seeing of work disability advisor because of RA,
n (%)
5 (3.4)
Sought assistance regarding employment since
onset of RA, n (%)
33 (22.3)
No. of hours worked per week, mean  SD 21.4  15.2
No. of hours lost per week, mean  SD 5.4  9.1
No. of hours lost per week because of RA,
mean  SD
4.9  9.1
Work performance affected by RA, mean  SD 50.9  30.5
HAQ-DI, Health Assessment Questionnaire – disability index; RA,
rheumatoid arthritis; RAQoL, Rheumatoid Arthritis Quality of Life;
RA-WIS, Rheumatoid Arthritis-Work Instability Scale.
* Range is 0–23, with higher scores reﬂecting greater disability risk.
† Categorization of RA-WIS scores: low risk (0–9), medium risk (10–
17), and high risk (18–23).
‡ Range 0–30, with higher scores reﬂecting worse HRQOL.
§ Range 0 (no difﬁculty) to 3 (unable to do).
ǁ Range 0 (no symptoms) to 100 (very active).
¶ Range 0 (no pain) to 100 (severe pain).
Table 2 – Construct validity at baseline and week 24:
Correlation between RA-WIS and clinical- and
patient-reported measures.
Measure RA-WIS* (N ¼ 148)
Week 0 Week 24
Duration of morning stiffness 0.31† 0.36‡
HAQ-DI 0.55§ 0.76§
DAS28 0.37§ 0.55§
Patient Global Assessment of Disease
Activity
0.47§ 0.66§
Patient Assessment of Pain 0.55§ 0.62§
Physician Global Assessment of
Disease Activity
0.31† 0.52§
RAQoL 0.77§ 0.81§
SJC28 0.07 0.46§
TJC28 0.35§ 0.55§
No. of hours lost per week because of
RA
0.37§ 0.27‡
No. of hours lost per week 0.30† 0.09
No. of hours worked per week –0.09 –0.12
Effect of RA on work performance 0.37§ 0.64§
DAS28, 28-Joint Disease Activity Score; HAQ-DI, Health Assess-
ment Questionnaire – disability index; RA, rheumatoid arthritis;
RA-WIS, Rheumatoid Arthritis-Work Instability Scale; RAQoL,
Rheumatoid Arthritis Quality of Life; SJC, swollen joint count;
TJC, tender joint count.
* Spearman rank correlation.
† P o 0.001.
‡ P o 0.05.
§ P o 0.0001.
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Reliability
Internal consistency reliability at baseline was 0.89 for the RA-
WIS. Pearson product-moment correlations between RA-WIS
total scores at screening (week –4) and baseline (week 0) were
high (r ¼ 0.91) and demonstrated substantial agreement between
test-retest scores (ICC ¼ 0.91).
Construct validity
Spearman correlation coefﬁcients between RA-WIS total scores
and clinical and PRO measures at baseline and week 24 were
moderate to strong for the HAQ-DI, Patient Global Assessment
of Disease Activity, and Patient Assessment of Pain and RAQoL,
ranging from 0.47 to 0.81 (all P o 0.0001) (Table 2). At baseline,
correlations with RA-WIS total scores were weaker for duration
of morning stiffness, DAS28, Physician Global Assessment of
Disease Activity, and TJC, ranging from 0.31 to 0.37 (all P o
0.001). Correlations with most of these measures were moder-
ate at week 24 (0.36 for duration of morning stiffness to 0.55 for
DAS28 and TJC; Po 0.05 and Po 0.0005, respectively). Although
the correlation between RA-WIS total and SJC scores at baseline
was weak and nonsigniﬁcant, a moderate, signiﬁcant correla-
tion was seen at week 24 (r ¼ 0.46; P o 0.0001). Consistently
across both time periods, the strongest associations were seenbetween the RA-WIS and the RAQoL, HAQ-DI, Patient Global
Assessment of Disease Activity, and Patient Global Assessment
of Pain.
Known-groups validity
RA-WIS total scores were able to discriminate between clinical
severity scores on the HAQ-DI, DAS28, and Physician Global
Assessment of Disease Activity and measures of work hours lost
because of RA. Mean RA-WIS scores by HAQ-DI categories were as
follows: 10.9 (HAQ-DI r0.88), 15.4 (HAQ-DI 40.88–1.38), 16.9
(HAQ-DI 41.38–1.75), and 18.8 (HAQ-DI 41.75) (P o 0.001)
(Fig. 1A). Mean RA-WIS scores by DAS28 categories were 3.74
(DAS28 r3.2), 11.82 (DAS28 43.2–5.1), and 16.33 (DAS28 45.1) (P
o 0.0001). Similar ﬁndings were seen for work hours lost per
week because of RA, where mean RA-WIS scores by lost hours
categories were 13.87 (no lost hours), 15.50 (r1 day lost per week),
and 16.9 (41 day lost per week) (P ¼ 0.0006) (Fig. 1B). The ﬁndings
were consistent at baseline and week 24. Similar ﬁndings were
seen when categorizing RA-WIS scores into work disability risk
levels (i.e., high, medium, low) (data not shown).
Responsiveness
Responsiveness of the RA-WIS to changes in disease activity was
evaluated by assessing the relationship between changes in RA-
WIS total scores and disease activity measures (i.e., ACR res-
ponder status and DAS28 remission status) from baseline to week
24 and from baseline to week 56 (Fig. 2A,B).
Mean baseline to week 24 RA-WIS total change scores were
signiﬁcantly different among ACR responder groups (i.e., ACR
o20%, Z20%–o50%, Z50%–o70%, and Z70%; P r 0.0001). Sim-
ilar ﬁndings were seen for RA-WIS total change scores from
baseline to week 56 (Fig. 2A) (Pr 0.0001). The greatest differences
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Fig. 1. – Known-groups validity of RA-WIS total score by HAQ scores. HAQ, Health Assessment Questionnaire; RA-WIS,
Rheumatoid Arthritis-Work Instability Scale.
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ments ranging from less than 20% to 20% and more to less than
50% in ACR (5.01 points), whereas the greatest differences at week56 were seen between ACR responder groups with improvements
ranging from 20% and more to less than 50% to 50% and more to
less than 70% in ACR (4.35 points).
-11.64
-10.7
-6.5
-7.22
-14
-12
-10
-8
-6
-4
-2
0
Baseline to Week 24*** Baseline to Week 56*
W
IS
 T
ot
al
 C
ha
ng
e 
Sc
or
es
DAS28 Remission Status over 24 and 56 Weeks
Responsiveness of RA-WIS Total Change Score by DAS28 Remission Status
DAS28 Remission DAS28 Non-Remission
-2.73
-2.46
-7.74
-5.31
-9.15
-9.66
-11.44 -11.31
-14
-12
-10
-8
-6
-4
-2
0
Baseline to Week 24*** Baseline to Week 56***
W
IS
 T
ot
al
 C
ha
ng
e 
Sc
or
es
ACR Responder Status over 24 and 56 Weeks
Responsiveness of RA-WIS Total Change Scores by ACR Responder Status
<20% ≥20% to <50% ≥50% to <70% ≥70%
(A)
(B)
Fig. 2. – Responsiveness of RA-WIS total change score by DAS28 remission status. DAS28, 28-Joint Disease Activity Score; RA-
WIS, Rheumatoid Arthritis-Work Instability Scale.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 0 8 – 1 0 1 5 1013RA-WIS total change scores from baseline to week 24 were
signiﬁcantly different based on DAS28 remission status, with
larger changes seen for patients in remission (DAS28 o 2.6) thanin those not in remission (DAS28 Z 2.6; P o 0.001). Similar
ﬁndings were seen for RA-WIS total change scores from baseline
to week 56 (Fig. 2B) (P r 0.0001). Differences between remission
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 0 8 – 1 0 1 51014and nonremission groups were 5.14 points at week 24 and 3.48
points at week 56.
Interpretation guidelines
Responder deﬁnitions can be developed on the basis of clinical
data from these analyses. For example, there was a –5.3 to –7.7
point RA-WIS score change associated with an improvement of
20% to less than 50% in ACR from baseline to 24 or 56 weeks.
There was a –5.4 to –6.1 point RA-WIS point change associated
with a moderate response for DAS28 at 24 or 56 weeks. These are
relatively large changes, given that the pooled baseline SD for the
RA-WIS was 5.5 in the PROWD clinical trial [7]. Based on the
current evidence, a responder deﬁnition of 5 points seems
reasonable. For the responder analyses in the planned clinical
trials, a decrease of 5 points in RA-WIS total scores will be used to
determine responders.Discussion
Measuring risk for work disability (i.e., WI) provides important
information from the patients’ perspective as to their potential to
remain in paid work and their experience with treatments used
to reduce the impact of RA on work outcomes. Psychometrically
sound instruments are necessary for assessing this construct.
This study expands on the initial assessment of measurement
properties for the RA-WIS conducted by the developers of this
instrument [19,23] and other researchers [22–24], providing fur-
ther supportive evidence that the RA-WIS is a reliable and valid
measure of WI in patients with RA. The RA-WIS total scores were
responsive to changes in clinical severity based on the ACR
criteria for improvement and DAS28 remission status experi-
enced over 24 and 56 weeks. Based on the study ﬁndings, the RA-
WIS is an acceptable measure for assessing work disability risk in
clinical studies of RA.
Internal consistency reliability of the RA-WIS total score
exceeded the recommended criterion of 0.70, considered sufﬁ-
cient for performing group-level comparisons [34,37], and dem-
onstrates a strong relationship among the RA-WIS items. Test-
retest reliability evaluation demonstrated excellent agreement
between RA-WIS total scores over 4 weeks in stable patients (ICC
¼ 0.91), suggesting that scores are replicable. These ﬁndings were
consistent with previously reported internal consistency reliabil-
ity of 0.92 [22] and test-retest reliability estimates of 0.89 [19].
Construct validity of the RA-WIS was supported by signiﬁcant
correlations between RA-WIS total scores and RA severity meas-
ures at baseline and 24 weeks. RA-WIS total scores were moder-
ately to strongly correlated with clinical and PRO measures such
as the HAQ-DI, Patient Global Assessment of Disease Activity,
Patient Assessment of Pain, RAQoL, DAS28, TJC, and SJC, suggest-
ing that clinical outcomes such as functional status and pain may
have a substantial inﬂuence on work disability risk. The magni-
tude of the correlations for disease-oriented constructs (as
described by Beaton et al.) is similar in both studies [22]. The
magnitude of the correlations for work-oriented constructs,
however, is lower for our study (0.09–0.38 absolute values)
compared with those reported previously by Beaton et al. (0.54–
0.73 absolute values). This may be a reﬂection of how the
construct of work impact was operationalized—where instru-
ments used in the present study reﬂect self-report of the number
of work hours lost per week (absenteeism) and instruments used
in the previous study reﬂect self-report of productivity, perform-
ance, and satisfaction, which may be more closely associated
with the construct assessed by the RA-WIS.
Mean RA-WIS total score and work disability risk levels varied
between clinical severity scores on the DAS28, HAQ-DI, and
Physician Global Assessment of Disease Activity, providingevidence further supporting construct validity. These results
demonstrated that patients with worse clinical outcomes (i.e.,
more severe disease activity and functional disability) had higher
risk for work disability. In addition, patients who lost more hours
per week from work because of RA had higher work disability
risk. The validity ﬁndings for the RA-WIS total score provide
further evidence supporting construct validity [22], whereas
ﬁndings for the work disability risk levels add new evidence
regarding the validity of using these levels on the impact of RA on
work outcomes.
Results of this study suggest that the RA-WIS total score was
responsive to clinically meaningful changes in disease activity,
conﬁrming and expanding on previous research [22]. On the basis
of DAS28 and ACR criteria at weeks 24 and 56, patients who
responded to therapy had greater improvements than did those
who responded less well and nonresponders, indicating a rela-
tionship between changes in clinical outcomes and changes in
work disability risk.
Based on the ACR and the DAS28 results, it is recommended
that an improvement of 5 points or more in RA-WIS total scores
may be considered clinically meaningful. This responder deﬁni-
tion needs to be conﬁrmed in additional clinical trials in patients
with RA.
Several limitations need to be considered when interpreting
the results of this study. First, no objective or independent
indicators of work performance were included in the study. The
evidence for construct validity was based on other PROs. Second,
the study design allowed patients to discontinue treatment after
16 weeks if they experienced loss of employment, lack of efﬁcacy,
or adverse effects. It is very unlikely, however, that the absence of
these patients from week 24 would affect the results of the
psychometric analyses. Third, the psychometric analyses were
based on a clinical trial sample, and therefore the results may not
be generalizable to the general population of patients with RA.
Clinical trial participants often have different demographic and
clinical characteristics than do the general population of patients
with early RA. The psychometric results from previous research
in clinical practice settings are consistent with the reliability and
validity ﬁndings reported in the present study [19,22,23].Conclusions
The results of this study suggest that the RA-WIS is reliable, valid,
and responsive to change and may be useful in assessing the
impact of disease and treatment on work disability risk in
patients with early RA. WI assessment may be most valuable in
clinical studies of interventions for early RA designed to prevent
work disability and work loss. The psychometric evidence sug-
gests that the RA-WIS may be an acceptable end point for clinical
trials comparing treatment outcomes for patients with early RA.
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